iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic sclerode...Show More
peer of
competitor of
Metrics
marketSTOCKS
msh_idCOM:IBIOINC
localeus
websitehttps://ibioinc.com
ipo_date2008-08-19
primary_stock_msh_idAMEX:IBIO
source_ref67fbc187-eecc-4363-9b0a-2d4a31da0284
products_or_servicesAntibody therapeutic development, AI-powered precision antibody identification and optimization, bispecifics, and antibody masking technology.